Optomed, an Oulu-based medical technology company, will supply a diabetic retinopathy screening solution consisting of Optomed Aurora IQ fundus cameras and related software solutions to a public sector end customer in Valencia, Spain.
The solution will be used to screen the local diabetic population for a potentially sight-threatening disease, diabetic retinopathy. The total contract value is approximately 800 000 euros, and the delivery has a positive effect on the Devices segment’s revenue for the second half of the year. It does not have an effect on Optomed’s financial outlook 2023.
‘I am extremely happy to see that our persistent work in Optomed is starting to turn into growing amounts of national-level screening solution deliveries to different countries. For years we have focused on our strategy to offer comprehensive screening solutions including camera and software products to diabetic retinopathy screening. Winning large tenders like this one in Spain are concrete indications that the demand for these screening solutions is growing and that our products are very competitive. We get to deliver our best technology to Spain‘ commented Seppo Kopsala, CEO at Optomed.
Optomed is one of the leading providers of handheld fundus cameras. The company combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of eye diseases such as rapidly increasing diabetic retinopathy. In its business, Optomed focuses on eye screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.
CEO, Optomed Plc